SUPN

49.19

1.15% 0.56

Dopo l'orario di chiusura: 50.00 0.81 +1.65%

Supernus Pharmaceuticals Inc (SUPN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché SUPN Giù? Forum Previsione

Precedente Chiudi:

$48.63

Aprire:

$49.07

Volume 24 ore:

1.11M

Relative Volume:

1.58

Capitalizzazione di mercato:

$2.85B

Reddito:

$718.95M

Utile/perdita netta:

$-38.55M

Rapporto P/E:

-71.93

EPS:

-0.6839

Flusso di cassa netto:

$45.99M

1 W Prestazione:

+1.03%

1M Prestazione:

-2.56%

6M Prestazione:

+4.42%

1 anno Prestazione:

+51.87%

Intervallo 1D:

$48.10

$50.55

Intervallo di 1 settimana:

$47.17

$50.55

Portata 52W:

$29.16

$59.68

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Nome

Supernus Pharmaceuticals Inc

Settore

Healthcare (1106)

Industria

Drug Manufacturers - Specialty & Generic (84)

Telefono

301-838-2500

Indirizzo

9715 KEY WEST AVENUE, ROCKVILLE, MD

Dipendente

778

Cinguettio

@Supernus_Pharma

Prossima data di guadagno

2026-05-05

Ultimi documenti SEC

SUPN's Discussions on Twitter

Compare SUPN vs TAK, ZTS, TEVA, HLN, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SUPN Supernus Pharmaceuticals Inc	49.19	2.82B	718.95M	-38.55M	45.99M	-0.6839
TAK Takeda Pharmaceutical Co Adr	16.55	52.32B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	112.54	47.38B	9.47B	2.67B	2.28B	6.0218
TEVA Teva Pharmaceutical Industries Ltd Adr	35.86	41.16B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.17	41.02B	14.54B	2.22B	2.58B	0.4871
UTHR United Therapeutics Corp	572.20	24.67B	3.18B	1.33B	1.04B	27.90

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-10-09	Aggiornamento	Piper Sandler	Neutral → Overweight
2025-07-30	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2025-02-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2025-01-06	Iniziato	Cantor Fitzgerald	Overweight
2024-09-11	Downgrade	Piper Sandler	Overweight → Neutral
2023-01-03	Ripresa	Jefferies	Buy
2021-12-01	Ripresa	Jefferies	Buy
2021-04-13	Aggiornamento	Jefferies	Hold → Buy
2020-06-16	Aggiornamento	Piper Sandler	Neutral → Overweight
2020-06-15	Ripresa	Jefferies	Hold
2019-11-08	Downgrade	Berenberg	Buy → Hold
2019-11-07	Downgrade	Stifel	Buy → Hold
2019-11-06	Downgrade	Jefferies	Buy → Hold
2018-11-12	Reiterato	B. Riley FBR	Buy
2018-01-18	Reiterato	B. Riley FBR, Inc.	Buy
2017-12-28	Reiterato	B. Riley FBR, Inc.	Buy
2017-12-04	Aggiornamento	Janney	Neutral → Buy
2017-11-08	Aggiornamento	Stifel	Hold → Buy
2017-10-19	Iniziato	FBR & Co.	Buy
2017-09-19	Downgrade	Stifel	Buy → Hold
2017-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
2017-07-14	Iniziato	Janney	Neutral
2017-06-01	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-07-18	Downgrade	Northland Capital	Outperform → Market Perform
2016-07-18	Downgrade	Piper Jaffray	Overweight → Neutral
2016-02-08	Aggiornamento	Jefferies	Hold → Buy
2015-11-05	Reiterato	Northland Capital	Outperform
2015-10-28	Iniziato	Northland Capital	Outperform

Mostra tutto

Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie

May 05, 2026

Supernus Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance

May 05, 2026

Supernus outlines $840M-$870M 2026 revenue outlook as ONAPGO second-supplier filing targeted for Q3 - MSN

May 05, 2026

Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

May 05, 2026

Supernus (SUPN) Q1 2026 Earnings Transcript - The Globe and Mail

May 05, 2026

Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat

May 05, 2026

Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance

May 05, 2026

Supernus Pharmaceuticals (SUPN) Stock Rises on Q1 2026 Earnings - Quiver Quantitative

May 05, 2026

SUPERNUS PHARMACEUTICALS ($SUPN) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative

May 05, 2026

Four newer Supernus drugs bring in $149.1M as 2026 outlook holds - Stock Titan

May 05, 2026

[10-Q] SUPERNUS PHARMACEUTICALS, INC. Quarterly Earnings Report - Stock Titan

May 05, 2026

Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates - Yahoo Finance

May 05, 2026

How Supernus Pharmaceuticals Inc. (SUPN) Affects Rotational Strategy Timing - Stock Traders Daily

May 04, 2026

Supernus Pharmaceuticals Earnings: What To Look For From SUPN - Yahoo Finance

May 04, 2026

Apr 30, 2026

[ARS] SUPERNUS PHARMACEUTICALS, INC. SEC Filing - Stock Titan

Apr 30, 2026

Supernus (NASDAQ: SUPN) sets 2026 virtual meeting on directors, pay and equity plan - Stock Titan

Apr 30, 2026

Vanguard (NASDAQ: SUPN) owns 2.9M Supernus shares, 5.03% stake - Stock Titan

Apr 30, 2026

Apr 29, 2026

Piper Sandler Upgrades Supernus Pharmaceuticals (SUPN) - MSN

Apr 29, 2026

Supernus finalizes $350M asset acquisition of Navitor’s SPN-820 - MSN

Apr 29, 2026

Vanguard Portfolio Management (NASDAQ: SUPN) holds 3.26M shares, 5.66% - Stock Titan

Apr 29, 2026

Apr 27, 2026

Supernus Signals Shift on Nasdaq Chart After Results - Kalkine Media

Apr 27, 2026

Branded Pharmaceuticals Stocks Q4 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - Yahoo Finance

Apr 27, 2026

Pharmaceutical Company Sued For Antitrust Appeals No D&O Coverage Ruling - Mealey's

Apr 27, 2026

BofA cuts Supernus Pharmaceuticals stock price target on costs By Investing.com - Investing.com Canada

Apr 27, 2026

Apr 24, 2026

A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong Recent Shareholder Returns - simplywall.st

Apr 24, 2026

Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise? - TradingView

Apr 24, 2026

Apr 23, 2026

(SUPN) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Apr 23, 2026

SUPN (Supernus Pharmaceuticals Inc.) delivers 142 percent Q4 2025 EPS surprise, shares rise 4.41 percent today.Shared Buy Zones - Cổng thông tin điện tử Tỉnh Sơn La

Apr 23, 2026

Apr 22, 2026

Supernus (SUPN) sets May 5 call to discuss Q1 2026 results - Stock Titan

Apr 22, 2026

Supernus will detail first-quarter results after markets close May 5 - Stock Titan

Apr 22, 2026

Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference ... - Caledonian Record

Apr 22, 2026

Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026 - GlobeNewswire

Apr 22, 2026

Apr 20, 2026

Supernus Pharmaceuticals (SUPN) Stock: Worth Holding? (Bearish Sentiment) 2026-04-20Community Momentum Stocks - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 20, 2026

Latest SUPN NewsSupernus Announces First Quarter 2020 Finan... - Stock Titan

Apr 20, 2026

Apr 18, 2026

Supernus Pharmaceuticals (SUPN) Stock DCF Valuation (Creeps Higher) 2026-04-18Sector Leader - Xã Thanh Hà

Apr 18, 2026

Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know - Yahoo Finance

Apr 18, 2026

Supernus Pharmaceuticals (SUPN) Stock: Trend Direction (Trend Strengthens) 2026-04-18Community Buy Signals - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 18, 2026

Apr 15, 2026

Q4 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus

Apr 15, 2026

Apr 13, 2026

MACD Signal: Is Supernus Pharmaceuticals Inc part of any major index2026 Year in Review & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Apr 13, 2026

Tudor Investment Corp ET AL Invests $1.43 Million in Supernus Pharmaceuticals - National Today

Apr 13, 2026

Apr 12, 2026

Responsive Playbooks and the SUPN Inflection - Stock Traders Daily

Apr 12, 2026

Apr 09, 2026